US Ophthalmology Association Warns Against Untested Avastin Alternatives
Discourages Using Pfizer’s Zirabev and Amgen’s Mvasi Biosimilars
Executive Summary
The American Academy of Ophthalmology has criticized healthcare insurers for pushing bevacizumab biosimilar alternatives to Avastin, like Pfizer’s Zirabev and Amgen’s Mvasi, that have not been subjected to clinical trials in eye disease or testing for retinal toxicity.
You may also be interested in...
Outlook’s Ophthalmic Bevacizumab Knocked Back By FDA
Outlook Therapeutics has received a CRL from the US FDA over its application for an ophthalmic formulation of bevacizumab. The company says it is working with the agency to address the various issues raised.
Outlook Refiles Ophthalmic Bevacizumab In US
Outlook Therapeutics has confirmed the re-submission of its proposed ophthalmic bevacizumab with the US Food and Drug Administration, after the agency requested further information.
US Biosimilar Approvals In 2021 Were Few But Included Many Firsts
While US biosimilar approvals have been somewhat thin on the ground in 2021 – with the pandemic driving inspection-related delays for multiple products – there were nevertheless several firsts this year, including the first two interchangeables and the first ophthalmic biosimilar.